Alterity Therapeutics Lim... (ATHE)
Alterity Therapeutics Statistics
Share Statistics
Alterity Therapeutics has 14.8M shares outstanding. The number of shares has increased by 38.7% in one year.
| Shares Outstanding | 14.8M |
| Shares Change (YoY) | 38.7% |
| Shares Change (QoQ) | 20.51% |
| Owned by Institutions (%) | 0% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 316 |
| FTD / Avg. Volume | 0.82% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.86 and the forward PE ratio is -5.31. Alterity Therapeutics's PEG ratio is 0.1.
| PE Ratio | -0.86 |
| Forward PE | -5.31 |
| PS Ratio | 4.09 |
| Forward PS | 13.1 |
| PB Ratio | 1.19 |
| P/FCF Ratio | -1.3 |
| PEG Ratio | 0.1 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Alterity Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.54, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.54 |
| Quick Ratio | 3.54 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $401,928.5 |
| Profits Per Employee | $-1,912,346.4 |
| Employee Count | 10 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 46.09K |
| Effective Tax Rate | -0.24% |
Stock Price Statistics
The stock price has increased by 60.75% in the last 52 weeks. The beta is 0.7, so Alterity Therapeutics's price volatility has been higher than the market average.
| Beta | 0.7 |
| 52-Week Price Change | 60.75% |
| 50-Day Moving Average | 3.54 |
| 200-Day Moving Average | 2.39 |
| Relative Strength Index (RSI) | 52.34 |
| Average Volume (20 Days) | 38,327 |
Income Statement
In the last 12 months, Alterity Therapeutics had revenue of 4.02M and earned -19.12M in profits. Earnings per share was -3.12.
| Revenue | 4.02M |
| Gross Profit | 3.8M |
| Operating Income | -19.6M |
| Net Income | -19.12M |
| EBITDA | -19.57M |
| EBIT | -19.61M |
| Earnings Per Share (EPS) | -3.12 |
Balance Sheet
The company has 12.64M in cash and 159.04K in debt, giving a net cash position of 12.48M.
| Cash & Cash Equivalents | 12.64M |
| Total Debt | 159.04K |
| Net Cash | 12.48M |
| Retained Earnings | -214.16M |
| Total Assets | 10.55M |
| Working Capital | 7.71M |
Cash Flow
In the last 12 months, operating cash flow was -12.61M and capital expenditures -5.72K, giving a free cash flow of -12.61M.
| Operating Cash Flow | -12.61M |
| Capital Expenditures | -5.72K |
| Free Cash Flow | -12.61M |
| FCF Per Share | 0 |
Margins
Gross margin is 94.67%, with operating and profit margins of -487.69% and -475.79%.
| Gross Margin | 94.67% |
| Operating Margin | -487.69% |
| Pretax Margin | -474.65% |
| Profit Margin | -475.79% |
| EBITDA Margin | -486.94% |
| EBIT Margin | -487.69% |
| FCF Margin | -313.78% |
Dividends & Yields
ATHE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ATHE is $12, which is 248.8% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12 |
| Price Target Difference | 248.8% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Jan 9, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | Jan 9, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -25.8 |
| Piotroski F-Score | 2 |